Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Borealis Foods (BRLS) Shares Outstanding (Diluted Average) (2023 - 2025)

Borealis Foods has reported Shares Outstanding (Diluted Average) over the past 3 years, most recently at $21.5 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $21.5 million for Q3 2025, changed 0.4% from a year ago — trailing twelve months through Sep 2025 was $21.5 million (changed 0.4% YoY), and the annual figure for FY2024 was $20.3 million, up 88.93%.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $21.5 million at Borealis Foods, roughly flat from $21.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for BRLS hit a ceiling of $21.5 million in Q3 2025 and a floor of $10.7 million in Q1 2023.
  • Median Shares Outstanding (Diluted Average) over the past 3 years was $19.2 million (2024), compared with a mean of $16.8 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 99.21% in 2024 and later rose 0.4% in 2025.
  • Borealis Foods' Shares Outstanding (Diluted Average) stood at $10.8 million in 2023, then surged by 88.93% to $20.3 million in 2024, then grew by 5.68% to $21.5 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $21.5 million (Q3 2025), $21.4 million (Q2 2025), and $21.4 million (Q1 2025) per Business Quant data.